Compare US Global Jets ETF (JETS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Repligen Corporation Common Stock — how do they compare? US Global Jets ETF trades at $26 (market cap $766.85M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 14.5× US Global Jets ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Repligen Corporation Common Stock for 0 Days on average.
| JETS | RGEN | |
|---|---|---|
Market Cap | $766.85M | $11.14B |
Volume | 3,093,704 | 1,259,263 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $194.57 |
52-Week Low | $23.64 | $102.87 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS is trading at $26.80, down 0.81% with a bearish technical outlook indicated by moving averages. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though strong travel demand provides some support. Recent news highlights underperformance compared to aerospace/defense ETFs, with fuel expenses surging 85% in May 2026 according to Reuters.
The outlook remains cautious due to fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term performance depends on fuel cost management and travel demand sustainability, with technical support at $26 providing a key level to watch.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
